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INTRODUCTION
Lupus nephritis is an important disease for nephrologists 
in Asia for three reasons. First, it is common. Indeed, 
data from mainland China has shown that it is the most 
common underlying systemic disease leading to renal 
biopsy [1]. Second, owing to the multifarious mani-
festations of the disease and its complications, the 
management of lupus nephritis is both challenging and 
educational. The clinician must be competent in handling 
immunosuppression, infections, and other complications 
related to different medical subspecialties. Also, the 
degree of clinical complexity often demands both clini-
cal acumen and experience in order for appropriate 
decisions to be made. Third, and a point that cannot be 
overemphasized, is that while the disease can be very 
severe and result in rapidly progressive renal failure, 
it is also very amenable to available treatments. The 
long-term prognosis can be favorable provided that 
diagnosis and treatment are not delayed.
Focal or diffuse proliferative lupus nephritis and 
membranous lupus nephritis are the varieties that most 
commonly call for the attention of the clinician. Our 
group has an established interest in the clinical studies 
on the therapeutics of lupus nephritis and the basic re-
search into its immunopathogenesis. This article gives 
an overview of our clinical studies over the past 15 years 
on severe lupus nephritis.
SEVERE PROLIFERATIVE LUPUS NEPHRITIS
Severe proliferative lupus nephritis typically presents 
with an acute nephritic syndrome, often accompanied 
by active serological markers, and results in rapid de-
struction of nephrons if untreated. Combination therapy 
with corticosteroid and cyclophosphamide has been the 
mainstay of immunosuppressive treatment for severe 
proliferative lupus nephritis since the 1970s, the basis 
of which is the observation that the addition of cyclo-
phosphamide resulted in more sustained remissions and 
better renal outcome compared with corticosteroid treat-
ment alone [2,3]. The use of combined corticosteroid 
and intravenous pulse cyclophosphamide as first-line 
treatment became popular after reports in the 1980s 
which demonstrated its efficacy in inducing remission 
and preventing relapses, and the lower incidence of 
adverse effects associated with intermittent intravenous 
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pulse cyclophosphamide compared with prolonged oral 
cyclophosphamide treatment. However, despite it being 
regarded as standard-of-care therapy for severe lupus 
nephritis, the long-term follow-up data on patients who 
were treated with this regimen have shown suboptimal 
renal survival and an alarming association between ex-
cessive mortality and cyclophosphamide exposure [4]. 
There was thus a pressing clinical need for an alternative 
to cyclophosphamide.
Mycophenolate mofetil—a new paradigm of 
treatment
The selective inhibitory action of mycophenolate mofetil 
on lymphocyte proliferation makes it an attractive can-
didate for the treatment of lupus, and the extensive ex-
perience in kidney transplant recipients demonstrating 
its high efficacy and favorable tolerability provided an 
encouraging impetus.
It has been more than 8 years since we published 
our initial results on mycophenolate mofetil in the treat-
ment of lupus nephritis, with that being the first prospec-
tive randomized clinical trial to compare mycophenolate 
mofetil against cyclophosphamide, given together with 
corticosteroid, in the treatment of diffuse proliferative 
lupus nephritis [5]. The objective of this proof-of-
concept 12-month study was to examine the efficacy 
and tolerability of combined prednisolone and myco-
phenolate mofetil treatment, in comparison with our 
then “standard therapy” of sequential immunosup-
pression. The latter started with prednisolone and oral 
cyclophosphamide as induction therapy, given for 
6 months, following which cyclophosphamide was 
substituted with azathioprine. Our results showed com-
parable efficacy between mycophenolate mofetil-based 
treatment and sequential immunosuppression, with both 
regimens inducing complete remission in around 80% 
and partial remission in 14% of patients. Unresponsive-
ness to immunosuppressive treatment was not observed. 
A distinct difference between the two treatments was 
the incidence and severity of treatment-related adverse 
effects. Mycophenolate mofetil treatment, at a starting 
dose of 1 g twice daily, then tapered after 6 months, was 
generally well tolerated. Leukopenia, alopecia, and 
amenorrhea were only observed in cyclophosphamide-
treated patients. The trend towards fewer infections in 
the mycophenolate mofetil group that was observed in 
the 12-month study achieved statistical significance 
when follow-up was extended to 3 years. The incidence 
of severe infections that required hospitalization was 
also lower in the mycophenolate group. The reduced 
incidence of adverse events during mycophenolate 
mofetil treatment was associated with a better quality 
of life and reduced time loss from work compared 
to cyclophosphamide induction [6]. Our results were 
subsequently confirmed by other investigators. All 
the studies have been consistent in demonstrating the 
efficacy, which is at least comparable to that of cyclo-
phosphamide, and tolerability of mycophenolate mofetil, 
which is much improved compared with cyclophospha-
mide. Furthermore, data from our extended observation 
after approximately 5 years of follow-up showed that 
the favorable short-term results were associated with a 
low rate of chronic renal failure [7].
Renal impairment in lupus nephritis can result from 
variable combinations of acute inflammatory lesions 
and chronic irreversible damage, and this presents a 
challenge in the selection and definition of study end-
points [8]. The rates of complete or partial remission 
are major endpoints in short-term therapeutic studies. 
Other investigators have previously shown that a 
follow-up duration of not shorter than 5 years would 
be necessary to discern the efficacy of a treatment 
regimen in terms of renal preservation, since deteriora-
tion of renal function following nephron loss is a rela-
tively slow and progressive process. Even longer 
follow-up durations would thus be required to reveal 
potential differences in renal survival rates when com-
paring different efficacious treatment regimens that 
result in a relatively small difference in nephron loss. 
Our data showed that serum creatinine in both treatment 
groups, continuous mycophenolate or sequential 
cyclophosphamide-azathioprine, remained stable over 
a median follow-up of 63 months [7]. While creatinine 
clearance increased significantly only in the mycophe-
nolate group, the between-group difference was not 
statistically significant. A relatively low percentage of 
patients (6% in the mycophenolate group and 10% in 
the cyclophosphamide-azathioprine group, p = 0.667) 
showed doubling of baseline creatinine during follow-
up. Our data also showed that prolonged treatment with 
mycophenolate mofetil for several years was well toler-
ated. However, the data to date from our group and 
others have not shown a significant difference in the 
rate of disease flares between patients receiving main-
tenance immunosuppression with mycophenolate 
mofetil or azathioprine [7,9].
Although the efficacy, high tolerability, and conve-
nience of administration associated with mycophenolate 
mofetil treatment present distinct advantages, access to 
therapy could be prohibited by its cost. Although it has 
been speculated that the high medication cost of myco-
phenolate can be partly offset by the reduced complica-
tions and hospitalization, the financial implications of 
treatment have remained undefined. Data from our re-
cent study showed that, while the cost of immunosup-
pressive drugs was approximately 14-fold higher in the 
mycophenolate mofetil treatment arm compared with 
cyclophosphamide-azathioprine sequential immunosup-
pression, the former was associated with an 80% reduc-
tion in the cost of treatment and hospitalization for 
infections. Con sequently, the overall treatment expen-
diture on immunosuppressive drugs, hospitalization and 
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treatment of infections was 1.57-fold higher in the 
mycophenolate group [10].
MEMBRANOUS LUPUS NEPHRITIS
In contrast to the proliferative varieties, pure membra-
nous lupus nephritis is less commonly associated with 
serologic activity, but is characterized by proteinuria 
and a relatively slow progression of renal function im-
pairment. It is not uncommon to encounter patients 
whose renal biopsies show both proliferative and mem-
branous features. According to the ISN/RPS 2003 
Classification for lupus nephritis, when subepithelial 
immune deposits or their light-microscopic morphologic 
sequelae involve ≥ 50% of the glomerular surface area 
in at least 50% of glomeruli, membranous lupus nephri-
tis should be diagnosed [11]. In this regard, the clinical 
course is critically influenced by the concomitant 
presence of proliferative lesions such as endocapillary 
proliferation and/or necrosis, since these portend a more 
aggressive disease process and are more often associated 
with serologic activity. Accordingly, there is general 
agreement that in patients with both proliferative and 
membranous lupus nephritis, the proliferative element 
is to assume priority with regard to immunosuppressive 
therapy.
There is marked diversity in the treatment of patients 
with pure membranous lupus nephritis. Treatment with 
corticosteroid alone has been associated with a response 
rate of less than one third. Consequently, patients have 
been treated with variable combinations of immunosup-
pressive agents including corticosteroid, azathioprine, 
and cyclophosphamide, and with inhibition or blockade 
of the renin–angiotensin system [12]. We have also 
investigated the efficacy and tolerability of sequential 
immunosuppression, comprising prednisolone and cy-
clophosphamide for 6 months followed by low-dose 
prednisolone and azathioprine maintenance, in mem-
branous lupus nephritis. In a cohort of 20 patients with 
pure membranous lupus nephritis and nephrotic syn-
drome, this sequential regimen induced complete remis-
sion in 55% and partial remission in 35% of patients 
within 12 months [13]. None of the patients developed 
hemorrhagic cystitis or permanent amenorrhea, but 40% 
had infectious complications, 15% had leukopenia, and 
40% of those who achieved remission had subsequent 
flares. Considering the relatively slow progression of 
renal failure, it may not be appropriate to subject patients 
with relatively mild symptoms to treatment regimens 
that could lead to severe adverse effects.
While the optimal therapy remains to be established, 
there is accumulating evidence to support a role for 
calcineurin inhibitors in the management of patients 
with persistent proteinuria due to membranous lupus 
nephritis. Tacrolimus offers the advantage of reduced 
cosmetic adverse effects compared with cyclosporine, 
which could be important in ensuring patient compli-
ance, although its adverse effects on blood pressure and 
glycemic control still warrant attention. In a pilot study 
on patients with membranous or inactive lupus nephritis 
who showed persistent proteinuria despite angiotensin 
inhibition and/or blockade, we showed that tacrolimus 
treatment effectively reduced proteinuria and increased 
serum albumin, so that > 80% of patients had their pro-
teinuria reduced by > 50% [14]. In those with biopsy-
proven membranous lupus nephritis, the proteinuria 
improved by > 80%. However, in view of the potential 
nephrotoxicity of these drugs, it is imperative that cir-
culating drug levels be regularly monitored and the 
lowest effective level be targeted.
In view of the potential adverse effects of the various 
treatment options, the choice of optimal treatment for 
membranous lupus nephritis should be informed by the 
severity of proteinuria. Persistent heavy proteinuria 
results in immediate complications such as peripheral 
edema, serous effusions, hypoalbuminemia, hypercho-
lesterolemia, and hypercoagulability. Important long-
term complications, which may not be evident in the 
early stage, include accelerated progression of renal 
failure and cardiovascular disease. Risk versus benefit 
considerations in the choice of treatment would thus 
vary according to the degree of proteinuria, with the 
minimization of proteinuria being an important treat-
ment objective.
CONCLUSIONS
It is encouraging that the management of lupus nephri-
tis and the clinical outcome of patients have improved 
significantly over the past few decades. This is due to 
advancements in both immunosuppressive treatment 
and supportive care. Improved immunosuppressive 
strategies relate not only to their potency, but also to a 
more advantageous benefit-to-risk ratio. In this regard, 
the advent of mycophenolate mofetil-based therapy has 
resulted in a reduced reliance on corticosteroid and a 
reduced incidence of treatment-related adverse effects 
compared with previous treatment regimens [15]. It is 
not difficult to appreciate why mycophenolate mofetil 
is preferred by doctors and patients, but it is of interest 
to note that the drug is increasingly covered by health 
insurance or health care providers despite the absence 
of formal regulatory approval in most countries. The 
latter is due to the accumulating favorable frontline clin-
ical experience which confirms the data from clinical 
trials, and to the efforts of clinicians, patient advocates, 
and health care administrators. There are, however, out-
standing issues that need to be resolved. For example, 
patients are still exposed to the adverse effects of corti-
costeroid. The optimal maintenance immunosuppressive 
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treatment to prevent disease flares also remains to be 
defined. It is hoped that further research will be able to 
provide answers to these questions. The research en-
deavor in lupus is reminiscent of a work of music, with 
the disparate pace and flavors of the different move-
ments culminating in an enriching experience.
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